Posted by Michael Wonder on 23 Aug 2018
NICE publishes preliminary guidance on new combo product for AML
23 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using liposomal cytarabine and daunorubicin in the NHS in England.
Liposomal cytarabine and daunorubicin is not recommended, within its anticipated marketing authorisation, for treating newly diagnosed, therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults.
The cost-effectiveness estimates for liposomal cytarabine and daunorubicin compared with standard cytaraine and daunorubicin are variable. This is mainly because of how long-term survival was estimated and included in the economic model.
Liposomal cytarabine and daunorubicin meets NICE’s criteria for being a life-extending treatment at the end of life. However, the most likely cost- effectiveness estimates are above the range that NICE normally considers acceptable. Therefore, liposomal cytarabine and daunorubicin is not recommended.
